Literature DB >> 30312530

Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.

Tanveen Ishaque1,2, Allan B Massie1,2, Mary G Bowring1, Christine E Haugen1, Jessica M Ruck1, Samantha E Halpern1, Madeleine M Waldram1, Macey L Henderson1, Jacqueline M Garonzik Wang1, Andrew M Cameron1, Benjamin Philosophe1, Shane Ottmann1, Anne F Rositch2, Dorry L Segev1,2.   

Abstract

Historically, exception points for hepatocellular carcinoma (HCC) led to higher transplant rates and lower waitlist mortality for HCC candidates compared to non-HCC candidates. As of October 2015, HCC candidates must wait 6 months after initial application to obtain exception points; the impact of this policy remains unstudied. Using 2013-2017 SRTR data, we identified 39  350 adult, first-time, active waitlist candidates and compared deceased donor liver transplant (DDLT) rates and waitlist mortality/dropout for HCC versus non-HCC candidates before (October 8, 2013-October 7, 2015, prepolicy) and after (October 8, 2015-October 7, 2017, postpolicy) the policy change using Cox and competing risks regression, respectively. Compared to non-HCC candidates with the same calculated MELD, HCC candidates had a 3.6-fold higher rate of DDLT prepolicy (aHR = 3.49 3.69 3.89 ) and a 2.2-fold higher rate of DDLT postpolicy (aHR = 2.09 2.21 2.34 ). Compared to non-HCC candidates with the same allocation priority, HCC candidates had a 37% lower risk of waitlist mortality/dropout prepolicy (asHR = 0.54 0.63 0.73 ) and a comparable risk of mortality/dropout postpolicy (asHR = 0.81 0.95 1.11 ). Following the policy change, the DDLT advantage for HCC candidates remained, albeit dramatically attenuated, without any substantial increase in waitlist mortality/dropout. In the context of sickest-first liver allocation, the revised policy seems to have established allocation equity for HCC and non-HCC candidates.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  cancer/malignancy/neoplasia; clinical research/practice; disparities; graft survival; liver disease: malignant; liver transplantation/hepatology; organ allocation

Year:  2018        PMID: 30312530      PMCID: PMC6349527          DOI: 10.1111/ajt.15144

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  11 in total

1.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

2.  Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.

Authors:  Julie K Heimbach; Ryutaro Hirose; Peter G Stock; David P Schladt; Hui Xiong; Jiannong Liu; Kim M Olthoff; Ann Harper; Jon J Snyder; Ajay K Israni; Bertram L Kasiske; W Ray Kim
Journal:  Hepatology       Date:  2015-02-24       Impact factor: 17.425

Review 3.  Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States.

Authors:  Susan Leppke; Tabitha Leighton; David Zaun; Shu-Cheng Chen; Melissa Skeans; Ajay K Israni; Jon J Snyder; Bertram L Kasiske
Journal:  Transplant Rev (Orlando)       Date:  2013-03-06       Impact factor: 3.943

4.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

5.  MELD Exceptions and Rates of Waiting List Outcomes.

Authors:  A B Massie; B Caffo; S E Gentry; E C Hall; D A Axelrod; K L Lentine; M A Schnitzler; A Gheorghian; P R Salvalaggio; D L Segev
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

Review 6.  Big data in organ transplantation: registries and administrative claims.

Authors:  A B Massie; L M Kucirka; L M Kuricka; D L Segev
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

7.  Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.

Authors:  Patrick Grant Northup; Nicolas Michael Intagliata; Neeral Lalit Shah; Shawn Joseph Pelletier; Carl Lansing Berg; Curtis Kent Argo
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

Review 8.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

9.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

10.  Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.

Authors:  Sarah K Alver; Douglas J Lorenz; Michael R Marvin; Guy N Brock
Journal:  Liver Transpl       Date:  2016-10       Impact factor: 5.799

View more
  16 in total

Review 1.  Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.

Authors:  Trevor W Reichman; Chandra S Bhati; Narendra R Battula
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

2.  Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.

Authors:  Eric Lee; Monika Sarkar; Jennifer Dodge; Maureen Kohi; Neil Mehta
Journal:  Transplantation       Date:  2020-05       Impact factor: 4.939

3.  The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.

Authors:  Sarah Bernards; Ryutaro Hirose; Francis Y Yao; Chengshi Jin; Jennifer L Dodge; Chiung-Yu Huang; Neil Mehta
Journal:  Liver Transpl       Date:  2021-12-08       Impact factor: 5.799

4.  Liver transplantation for colorectal liver metastasis: aiming for a cure or a palliation?

Authors:  Axel Andres; Gonzalo Sapisochin; Silvio Nadalin; René Adam; Christian Toso
Journal:  Transpl Int       Date:  2021-11       Impact factor: 3.842

5.  Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Authors:  Reham Abdel-Wahab; Manal M Hassan; Bhawana George; Roberto Carmagnani Pestana; Lianchun Xiao; Sahin Lacin; Suayib Yalcin; Ahmed S Shalaby; Humaid O Al-Shamsi; Kanwal Raghav; Robert A Wolff; James C Yao; Lauren Girard; Abedul Haque; Dan G Duda; Simona Dima; Irinel Popescu; Hesham A Elghazaly; Jean-Nicolas Vauthey; Thomas A Aloia; Ching-Wei Tzeng; Yun Shin Chun; Asif Rashid; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncology       Date:  2020-10-07       Impact factor: 2.935

6.  How do highly sensitized patients get kidney transplants in the United States? Trends over the last decade.

Authors:  Kyle R Jackson; Jennifer D Motter; Amber Kernodle; Niraj Desai; Alvin G Thomas; Allan B Massie; Jacqueline M Garonzik-Wang; Dorry L Segev
Journal:  Am J Transplant       Date:  2020-03-12       Impact factor: 8.086

7.  Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.

Authors:  Max N Brondfield; Jennifer L Dodge; Ryutaro Hirose; Julie Heimbach; Francis Y Yao; Neil Mehta
Journal:  Liver Transpl       Date:  2020-05       Impact factor: 5.799

8.  Early Allograft Dysfunction Increases Hospital Associated Costs After Liver Transplantation-A Propensity Score-Matched Analysis.

Authors:  Simon Moosburner; Igor M Sauer; Frank Förster; Thomas Winklmann; Joseph Maria George Vernon Gassner; Paul V Ritschl; Robert Öllinger; Johann Pratschke; Nathanael Raschzok
Journal:  Hepatol Commun       Date:  2020-12-05

9.  Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.

Authors:  Neehar D Parikh; Amit G Singal; David W Hutton; Elliot B Tapper
Journal:  Am J Gastroenterol       Date:  2020-10       Impact factor: 12.045

10.  Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma.

Authors:  Mohamed Saleh Ismail; Islam Mohamed; Efstathia Polychronopoulou; John A Goss; Yong-Fang Kuo; Fasiha Kanwal; Prasun K Jalal
Journal:  J Hepatocell Carcinoma       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.